Which has higher valuation and earnings, NVS or AZN?

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.10 $13.98B $6.98 20.86 Astrazeneca $58.74B 4.75 $10.23B $6.66 27.01

Is NVS or AZN more profitable?

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Astrazeneca 17.19% 30.86% 12.68%

Does the media prefer NVS or AZN?

In the previous week, Astrazeneca had 4 more articles in the media than Novartis. MarketBeat recorded 10 mentions for Astrazeneca and 6 mentions for Novartis. Astrazeneca's average media sentiment score of 0.43 beat Novartis' score of -0.13 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Astrazeneca 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Novartis 24.87% 38.82% 15.16%

Does the media refer more to NVO or NVS?

In the previous week, Novo Nordisk A/S had 24 more articles in the media than Novartis. MarketBeat recorded 30 mentions for Novo Nordisk A/S and 6 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.74 beat Novartis' score of -0.13 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 15 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Novartis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.11 $8.84B $3.58 12.00 Novartis $54.53B 5.10 $13.98B $6.98 20.86

Is SNY or NVS more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novartis 24.87% 38.82% 15.16%

Does the media favor SNY or NVS?

In the previous week, Novartis had 3 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Novartis and 3 mentions for Sanofi. Sanofi's average media sentiment score of 1.01 beat Novartis' score of -0.13 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.32 $7.54B $3.85 12.79 Novartis $54.53B 5.10 $13.98B $6.98 20.86

Is GSK or NVS more profitable?

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Novartis 24.87% 38.82% 15.16%

Does the media refer more to GSK or NVS?

In the previous week, GSK had 8 more articles in the media than Novartis. MarketBeat recorded 14 mentions for GSK and 6 mentions for Novartis. GSK's average media sentiment score of 0.48 beat Novartis' score of -0.13 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novartis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer NVS or TAK?

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 3.05%. Given Novartis' higher possible upside, equities research analysts clearly believe Novartis is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novartis 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.31 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Novartis (NVS) Competitors

$145.64 -4.53 (-3.02%)

Closing price 03:59 PM Eastern

Extended Trading

$146.64 +1.01 (+0.69%)

As of 05:04 PM Eastern

Compare

NVS vs. AZN, NVO, SNY, GSK, and TAK

Should you buy Novartis stock or one of its competitors? MarketBeat compares Novartis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Novartis compare to Astrazeneca?

Novartis (NYSE:NVS) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Novartis has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

In the previous week, Astrazeneca had 4 more articles in the media than Novartis. MarketBeat recorded 10 mentions for Astrazeneca and 6 mentions for Novartis. Astrazeneca's average media sentiment score of 0.43 beat Novartis' score of -0.13 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Astrazeneca	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

13.1% of Novartis shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Astrazeneca	17.19%	30.86%	12.68%

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Novartis pays out 44.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 3.05%. Astrazeneca has a consensus price target of $205.33, indicating a potential upside of 14.14%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.10	$13.98B	$6.98	20.86
Astrazeneca	$58.74B	4.75	$10.23B	$6.66	27.01

Summary

Novartis and Astrazeneca tied by winning 9 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Novo Nordisk A/S presently has a consensus price target of $65.56, suggesting a potential upside of 48.96%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 3.05%. Given Novo Nordisk A/S's higher probable upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.0%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	24.87%	38.82%	15.16%

Novo Nordisk A/S has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 24 more articles in the media than Novartis. MarketBeat recorded 30 mentions for Novo Nordisk A/S and 6 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.74 beat Novartis' score of -0.13 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	15 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Novartis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.20	$15.51B	$4.26	10.33
Novartis	$54.53B	5.10	$13.98B	$6.98	20.86

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novartis	24.87%	38.82%	15.16%

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Sanofi presently has a consensus target price of $51.00, suggesting a potential upside of 18.72%. Novartis has a consensus target price of $141.20, suggesting a potential downside of 3.05%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, Novartis had 3 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Novartis and 3 mentions for Sanofi. Sanofi's average media sentiment score of 1.01 beat Novartis' score of -0.13 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.11	$8.84B	$3.58	12.00
Novartis	$54.53B	5.10	$13.98B	$6.98	20.86

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to GSK?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

15.7% of GSK shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, GSK had 8 more articles in the media than Novartis. MarketBeat recorded 14 mentions for GSK and 6 mentions for Novartis. GSK's average media sentiment score of 0.48 beat Novartis' score of -0.13 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novartis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

GSK presently has a consensus target price of $53.00, suggesting a potential upside of 7.65%. Novartis has a consensus target price of $141.20, suggesting a potential downside of 3.05%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novartis	24.87%	38.82%	15.16%

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. GSK pays out 47.0% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.32	$7.54B	$3.85	12.79
Novartis	$54.53B	5.10	$13.98B	$6.98	20.86

Summary

Novartis beats GSK on 11 of the 18 factors compared between the two stocks.

How does Novartis compare to Takeda Pharmaceutical?

Novartis (NYSE:NVS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.3%. Novartis pays out 44.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Novartis has higher revenue and earnings than Takeda Pharmaceutical. Novartis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.10	$13.98B	$6.98	20.86
Takeda Pharmaceutical	$28.32B	1.71	$1.27B	$0.39	38.96

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 3.05%. Given Novartis' higher possible upside, equities research analysts clearly believe Novartis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Novartis had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Novartis and 0 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.84 beat Novartis' score of -0.13 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Overall Sentiment
Novartis	Neutral
Takeda Pharmaceutical	Positive

Novartis has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Novartis has a net margin of 24.87% compared to Takeda Pharmaceutical's net margin of 4.31%. Novartis' return on equity of 38.82% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Summary

Novartis beats Takeda Pharmaceutical on 13 of the 18 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$277.90B	$299.91B	$6.31B	$23.23B
Dividend Yield	2.05%	2.76%	2.68%	4.09%
P/E Ratio	20.86	26.75	21.13	30.90
Price / Sales	5.10	4.95	546.80	24.79
Price / Cash	13.98	13.10	27.44	19.43
Price / Book	6.61	7.65	9.95	4.72
Net Income	$13.98B	$11.61B	$3.56B	$1.07B
7 Day Performance	-4.28%	-3.60%	2.15%	1.38%
1 Month Performance	N/A	N/A	N/A	0.51%
1 Year Performance	25.91%	19.76%	36.47%	27.95%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	3.1451 of 5 stars	$145.64 -3.0%	$141.20 -3.0%	+29.9%	$277.90B	$54.53B	20.86	75,267	Gap Down
AZN Astrazeneca	3.9626 of 5 stars	$185.79 -0.8%	$205.33 +10.5%	N/A	$288.14B	$58.74B	27.90	96,100	Analyst Forecast
NVO Novo Nordisk A/S	4.3612 of 5 stars	$44.59 +0.9%	$65.56 +47.0%	-36.2%	$199.10B	$327.80B	10.47	69,505
SNY Sanofi	4.7141 of 5 stars	$44.43 +0.6%	$51.00 +14.8%	-11.6%	$108.36B	$47.35B	12.41	74,846
GSK GSK	2.8023 of 5 stars	$51.56 +0.1%	$53.00 +2.8%	+23.2%	$104.62B	$32.78B	13.40	66,841	Dividend Cut Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Which has more volatility & risk, NVS or AZN?

Does the media prefer NVS or AZN?

Do insiders and institutionals believe in NVS or AZN?

Is NVS or AZN more profitable?

Is NVS or AZN a better dividend stock?

Do analysts recommend NVS or AZN?

Which has higher valuation and earnings, NVS or AZN?

Summary

How does Novartis compare to Novo Nordisk A/S?

Do analysts recommend NVO or NVS?

Do insiders and institutionals hold more shares of NVO or NVS?

Is NVO or NVS a better dividend stock?

Is NVO or NVS more profitable?

Which has more risk & volatility, NVO or NVS?

Does the media refer more to NVO or NVS?

Which has better earnings & valuation, NVO or NVS?

Summary

How does Novartis compare to Sanofi?

Is SNY or NVS more profitable?

Is SNY or NVS a better dividend stock?

Do analysts rate SNY or NVS?

Does the media favor SNY or NVS?

Do institutionals and insiders hold more shares of SNY or NVS?

Which has more risk & volatility, SNY or NVS?

Which has higher valuation and earnings, SNY or NVS?

Summary

How does Novartis compare to GSK?

Which has more volatility & risk, GSK or NVS?

Do institutionals & insiders believe in GSK or NVS?

Does the media refer more to GSK or NVS?

Do analysts recommend GSK or NVS?

Is GSK or NVS more profitable?

Is GSK or NVS a better dividend stock?

Which has stronger valuation & earnings, GSK or NVS?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Is NVS or TAK a better dividend stock?

Which has better valuation & earnings, NVS or TAK?

Do analysts prefer NVS or TAK?

Does the media prefer NVS or TAK?

Which has more volatility & risk, NVS or TAK?

Do institutionals and insiders believe in NVS or TAK?

Is NVS or TAK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools